FSD Pharma Inc. | WebDisclosure

Basculer en Français

10925	Companies
238417	Keywords
167224	Articles
128086	Press releases

Home
Companies
FSD Pharma Inc.

PRESS RELEASE

published on 02/26/2024 at 14:00, 2 years 6 months ago

FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM)
FSD Pharma Inc. announced an agreement for a clinical trial to test unbuzzd™ effects on faster alcohol metabolism. The trial aims to confirm the supplement's potential benefits in sobering up from alcohol intoxication

FSD Pharma Inc. Biopharmaceutical Clinical Trial Unbuzzd™ Alcohol Metabolism
BRIEF

published on 02/26/2024 at 14:00, 2 years 6 months ago

FSD Pharma launches a clinical trial to test the effectiveness of unbuzzd™

FSD Pharma Clinical Test Unbuzzd™ Alcohol Metabolism Accelerated Sobriety
BRIEF

published on 02/26/2024 at 14:00, 2 years 6 months ago

FSD Pharma lance un essai clinique pour tester l'efficacité d'unbuzzd™

FSD Pharma Essai Clinique Unbuzzd™ Métabolisme De L'alcool Sobriété Accélérée
PRESS RELEASE

published on 02/17/2024 at 01:10, 2 years 6 months ago

FSD Pharma Announces US ATM Offering
FSD Pharma announces an at-the-market offering agreement with H.C. Wainwright & Co., LLC to sell Class B Shares for up to US$11,154,232. The Company may use proceeds for clinical trials & general corporate purposes

FSD Pharma Biopharmaceutical At-the-market Offering H.C. Wainwright & Co. Class B Shares
PRESS RELEASE

published on 02/06/2024 at 13:00, 2 years 6 months ago

Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million
FSD Pharma Inc. announced that the Court of Appeal for Ontario affirmed the Judgment entered by the Superior Court of Justice. The company also filed a Petition to Confirm Arbitration Awards in the United States District Court for the Eastern District of Pennsylvania

FSD Pharma Inc. Court Of Appeal Biopharmaceutical Arbitration Awards Neurodegenerative Disorders
PRESS RELEASE

published on 01/29/2024 at 22:30, 2 years 7 months ago

FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates
FSD Pharma appoints Dr. Sanjiv Chopra to its board of directors, replaces Nitin Kaushal. Also, the company retains SBS Intl Group LLC, Draper Inc., Carriage House Capital, Corp., IR Agency, Beyond Media, Issuer Direct for various services. FSD focuses on biopharmaceutical assets

FSD Pharma Dr. Sanjiv Chopra Biopharmaceutical SBS Intl Group LLC IR Agency
PRESS RELEASE

published on 01/16/2024 at 13:30, 2 years 7 months ago

Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot
FSD Pharma Inc., a biopharmaceutical company, provides an update on its litigation with GBB Drink Lab, Inc., denying allegations and moving for discovery. The company remains confident in its legal position and looks forward to vindicating its rights and exposing GBB and its bully tactics.

Biopharmaceutical Company FSD Pharma Inc. Litigation Update GBB Drink Lab Inc. Alcohol Detoxification
PRESS RELEASE

published on 12/23/2023 at 01:45, 2 years 8 months ago

FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC
PRESS RELEASE

published on 12/05/2023 at 15:00, 2 years 8 months ago

FSD Pharma Inc. Announces Closing of Private Placement
FSD Pharma Inc. announces the closing of private placement and issuance of class A multiple voting shares at $1.90 per share for gross proceeds of $45.60. The proceeds will be used for general working capital purposes

Private Placement FSD Pharma Inc. Financial News Investment Class A Multiple Voting Shares
PRESS RELEASE

published on 11/30/2023 at 14:30, 2 years 9 months ago

FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement
FSD Pharma Inc. and Celly Nutrition Corp. announce completion of Plan of Arrangement including distribution of Celly Nu Shares and New FSD Pharma Securities to FSD Pharma securityholders

FSD Pharma Inc. Plan Of Arrangement Celly Nutrition Corp. Celly Nu Shares New FSD Pharma Securities

Accesswire

Published on 09/03/2026 at 12:00, 45 minutes ago

NuRAN Wireless Announces Creation of NuEnergy, a Solar, Storage and Hybrid Power Subsidiary
Published on 09/02/2026 at 22:55, 13 hours 50 minutes ago

Secure Blockchain Sells Delivery Trust(R) Business
Published on 09/02/2026 at 18:45, 18 hours ago

Full Circle Lithium Rebrands as FCL-X Fire & Safety Inc. and Provides Corporate Update
Published on 09/02/2026 at 15:00, 21 hours 45 minutes ago

Vox Royalty Enters into Binding Agreement to Acquire the White Dam Gold Royalty in Australia
Published on 09/02/2026 at 14:30, 22 hours 15 minutes ago

Solitario Completes Phase-One Drilling at Golden Crest - Reports Initial Drill Results for Ponderosa

View all ACCESSWIRE

EQS Group

Published on 09/03/2026 at 12:05, 39 minutes ago

EXIN launches the AI Security Professional certification, built on the OWASP AI Exchange -- making AI security skills transparent and verifiable
Published on 09/03/2026 at 11:45, 59 minutes ago

Gan & Lee and Menarini Group Partner to Advance Bofanglutide in Europe
Published on 09/03/2026 at 11:30, 1 hour 14 minutes ago

u-blox enhances GNSS timing validation with nanosecond-accurate METAS time service
Published on 09/03/2026 at 11:30, 1 hour 14 minutes ago

Four Years of Partnership, Striving for Excellence | XTrend Speed × AFA Renew Sponsorship for the Fourth Consecutive Year
Published on 09/03/2026 at 11:00, 1 hour 45 minutes ago

ABB Ltd: ABB share buybacks - August 27, 2026 - September 2, 2026

Les Echos

Published on 09/03/2026 at 09:00, 3 hours 45 minutes ago

Transfert effectif des titres Gerard Perrier Industrie sur Euronext Growth Paris à compter du 7 septembre 2026
Published on 09/03/2026 at 07:00, 5 hours 45 minutes ago

Excellent portfolio performance leads to a 7.5% increase in Net Asset Value to EUR 57.2 per share
Published on 09/03/2026 at 07:00, 5 hours 45 minutes ago

Excellent portfolio performance leads to a 7.5% increase in Net Asset Value to EUR 57.2 per share
Published on 09/03/2026 at 07:00, 5 hours 45 minutes ago

Uitstekende portefeuilleprestaties leiden tot stijging van de intrinsieke waarde met 7,5% tot EUR 57,2 per aandeel
Published on 09/02/2026 at 21:30, 15 hours 15 minutes ago

Accor announces the success of OCEANEs due 2032 for a nominal amount of €380 million and the results of the partial repurchase of its outstanding OCEANEs due 2027

View all LES ECHOS COMFI WIRE